FDA Clearance Tracker · K261212
Flowflex Plus RSV + Flu A/B + COVID Rapid Test
Last checked: Nov 20, 2026Latest source record: Jul 10, 2026 (this decision)Source: openFDAMethods & limitations
Decided
Jul 10, 2026
Substantially Equivalent
Time to decision
87 days
Received Apr 14, 2026. Calendar days, including time FDA spent waiting on the applicant.
Pathway
510(k)
Dual Track
Device class
Class II
The decision
- FDA number
- K261212
- Device name
- Flowflex Plus RSV + Flu A/B + COVID Rapid Test
- Applicant
- ACON Laboratories, Inc.
- Applicant location
- San Diego, CA
- Received
- Apr 14, 2026
- Decided
- Jul 10, 2026
- Decision
- Substantially Equivalent
- Submission type
- Dual Track
Device type
- Device class
- Class II
- Regulation
- 21 CFR 866.3987
- Specialty
- Laboratory Medicine & Pathology
How new is this?
These are facts about FDA's records. They are not a judgment about the device.
- It is not the first decision under product code SCA. The earliest in FDA's data is DEN240029, decided Oct 7, 2024.
- It is not on FDA's public list of Breakthrough Devices with marketing authorization (list dated June 30, 2026). FDA does not publish which devices hold the designation before they are authorized, and the list is updated only a few times a year.
Source documents
- FDA database record for K261212
- The applicant filed a statement instead of a public summary, or the summary is not at FDA's usual address. Check the FDA record.
The predicate devices this clearance relied on are named in the summary document. We do not extract them yet.
Other decisions for ACON Laboratories, Inc.
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
K251697 · Decided Nov 26, 2025 · 177 days after receipt
Device type: Antigens, All Groups, Streptococcus Spp. (GTY) · Laboratory Medicine & Pathology
K251749 · Decided Oct 22, 2025 · 138 days after receipt
Device type: Multi-Analyte Respiratory Virus Antigen Detection Test (SCA) · Laboratory Medicine & Pathology
K250085 · Decided Oct 10, 2025 · 270 days after receipt
Device type: System, Test, Blood Glucose, Over The Counter (NBW) · Laboratory Medicine & Pathology
5 more FDA decisions with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.